Familial Hypercholesterolemia
Familial hypercholesterolemia (FH) is a genetic disorder that results in high levels of cholesterol in the blood, which can lead to early heart disease if not managed properly.
Familial Hypercholesterolemia: Inclisiran Safety Study
We are studying the long-term safety and tolerability of inclisiran in individuals with familial hypercholesterolemia who have completed earlier studies. This research aims to understand how well the treatment works over time.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you a male or female who completed the ORION-16 or ORION-13 studies?
- Did you benefit from treatment with inclisiran in the ORION-16 or ORION-13 studies?
- Are you currently taking lipid-lowering medications like statins or ezetimibe without any planned changes?
- Do you have any serious health issues that could interfere with your participation in this study?
- Do you have any active liver disease, such as hepatitis or cirrhosis?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Vseobecna Fakultni Nemocnice V Praze
#2851, Klinika pediatrie a dědičných poruch metabolismu
Prague, Czechia
Fakultni Nemocnice V Motole
#2850, ÚLCHKB
Stodůlky, Czechia
Hopital Des Enfants
#2102:Equipe de gastroentérologie, hépatologie, nutrition et maladies héréditaires du métabolisme
Blagnac, France
Sponsor: Novartis Pharma AG
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.